Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 40% of FD Patients Complain of Abdominal Distention
January 23, 2006
- 3 New Procedures to Be Covered by Insurance in April
January 23, 2006
- R&D NEWS IN BRIEF
January 23, 2006
- NEW PRODUCTS
January 23, 2006
- TOPICS 3 articles
January 23, 2006
- JPMA Approves FY2006 Action Plan
January 23, 2006
- Review Process Will Be Speeded Up in 2nd Half of FY2006: PMDA Director Miyajima
January 23, 2006
- SEMINAR
January 23, 2006
- Mr Matsutani of HPB Supports Revised Prescription Form
January 23, 2006
- Eligibility Criteria for DPC Approved: Chuikyo
January 23, 2006
- Korosho Proposes Addition, Not Replacement of Prescription Form
January 23, 2006
- REGULATORY NEWS IN BRIEF
January 16, 2006
- Nippon Shinyaku Licenses CML Treatment NS-187 to INNOVIVE of the US
January 16, 2006
- BUSINESS NEWS IN BRIEF
January 16, 2006
- SELF-MEDICATION NEWS IN BRIEF
January 16, 2006
- More Drugs to Come from Bio-ventures than Drug Firms: Prof. Morishita of AnGes MG
January 16, 2006
- Pharma Industry Invested \906.7 Bil. in R&D in FY2004
January 16, 2006
- JMA to Support IIT through Training, Information Supply
January 16, 2006
- Mr Takeda of FPMAJ Stresses Importance of Market Price Principle
January 16, 2006
- R&D NEWS IN BRIEF
January 16, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…